Roche Holding AG
RHHBY
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
103,249
Roche Holding AG News & Analysis
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
stocks
The 10 best global companies to invest in now
These undervalued stocks of high-quality companies are attractive investments today.
stocks
5 top US dividend shares from the best managers
These cheap dividend stocks are popular among highly rated concentrated fund managers.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,293.20 | 45.10 | -0.48% |
CAC 40 | 8,174.20 | 14.39 | -0.18% |
DAX 40 | 23,830.99 | 441.20 | -1.82% |
Dow JONES (US) | 46,190.61 | 238.37 | 0.52% |
FTSE 100 | 9,354.57 | 81.52 | -0.86% |
HKSE | 25,247.10 | 641.41 | -2.48% |
NASDAQ | 22,679.97 | 117.44 | 0.52% |
Nikkei 225 | 47,582.15 | 695.59 | -1.44% |
NZX 50 Index | 13,289.21 | 99.89 | -0.75% |
S&P 500 | 6,664.01 | 34.94 | 0.53% |
S&P/ASX 200 | 8,995.30 | 34.70 | -0.38% |
SSE Composite Index | 3,839.76 | 76.47 | -1.95% |